John Newman
Stock Analyst at Canaccord Genuity
(2.13)
# 2,936
Out of 5,149 analysts
89
Total ratings
44.87%
Success rate
-6.32%
Average return
Main Sectors:
Stocks Rated by John Newman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ATRA Atara Biotherapeutics | Downgrades: Hold | $25 → $6 | $5.42 | +10.70% | 7 | Jan 13, 2026 | |
| ACET Adicet Bio | Maintains: Buy | $128 → $18 | $7.02 | +156.41% | 7 | Jan 6, 2026 | |
| ACLX Arcellx | Maintains: Buy | $130 | $114.05 | +13.99% | 10 | Dec 8, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Buy | $850 → $1,057 | $766.66 | +37.87% | 20 | Dec 4, 2025 | |
| CMPX Compass Therapeutics | Initiates: Buy | $10 | $5.53 | +80.83% | 1 | Dec 3, 2025 | |
| NUVL Nuvalent | Initiates: Buy | $126 | $100.22 | +25.72% | 1 | Nov 12, 2025 | |
| DCTH Delcath Systems | Maintains: Buy | $21 | $8.60 | +144.19% | 2 | Oct 21, 2025 | |
| MCRB Seres Therapeutics | Maintains: Buy | $14 → $22 | $8.80 | +150.00% | 10 | Sep 24, 2025 | |
| ALLO Allogene Therapeutics | Maintains: Buy | $14 | $2.53 | +453.36% | 3 | Mar 14, 2025 | |
| BNTX BioNTech SE | Maintains: Buy | $171 | $100.76 | +70.15% | 8 | Mar 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $1.37 | +483.94% | 1 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $25 | $4.91 | +409.16% | 2 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $38 → $43 | $7.48 | +474.87% | 1 | Jul 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $5 | $1.04 | +380.77% | 2 | Jun 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $52 → $44 | $28.48 | +54.49% | 9 | Feb 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $30 → $38 | $13.49 | +181.79% | 2 | Oct 17, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $27 | $5.11 | +428.38% | 2 | Sep 13, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Speculative Buy | n/a | $14.15 | - | 1 | Sep 13, 2017 |
Atara Biotherapeutics
Jan 13, 2026
Downgrades: Hold
Price Target: $25 → $6
Current: $5.42
Upside: +10.70%
Adicet Bio
Jan 6, 2026
Maintains: Buy
Price Target: $128 → $18
Current: $7.02
Upside: +156.41%
Arcellx
Dec 8, 2025
Maintains: Buy
Price Target: $130
Current: $114.05
Upside: +13.99%
Regeneron Pharmaceuticals
Dec 4, 2025
Maintains: Buy
Price Target: $850 → $1,057
Current: $766.66
Upside: +37.87%
Compass Therapeutics
Dec 3, 2025
Initiates: Buy
Price Target: $10
Current: $5.53
Upside: +80.83%
Nuvalent
Nov 12, 2025
Initiates: Buy
Price Target: $126
Current: $100.22
Upside: +25.72%
Delcath Systems
Oct 21, 2025
Maintains: Buy
Price Target: $21
Current: $8.60
Upside: +144.19%
Seres Therapeutics
Sep 24, 2025
Maintains: Buy
Price Target: $14 → $22
Current: $8.80
Upside: +150.00%
Allogene Therapeutics
Mar 14, 2025
Maintains: Buy
Price Target: $14
Current: $2.53
Upside: +453.36%
BioNTech SE
Mar 11, 2025
Maintains: Buy
Price Target: $171
Current: $100.76
Upside: +70.15%
Mar 5, 2025
Initiates: Buy
Price Target: $8
Current: $1.37
Upside: +483.94%
Feb 26, 2025
Maintains: Buy
Price Target: $20 → $25
Current: $4.91
Upside: +409.16%
Jul 3, 2024
Maintains: Buy
Price Target: $38 → $43
Current: $7.48
Upside: +474.87%
Jun 23, 2023
Reiterates: Buy
Price Target: $5
Current: $1.04
Upside: +380.77%
Feb 16, 2022
Maintains: Buy
Price Target: $52 → $44
Current: $28.48
Upside: +54.49%
Oct 17, 2017
Maintains: Buy
Price Target: $30 → $38
Current: $13.49
Upside: +181.79%
Sep 13, 2017
Maintains: Buy
Price Target: $12 → $27
Current: $5.11
Upside: +428.38%
Sep 13, 2017
Downgrades: Speculative Buy
Price Target: n/a
Current: $14.15
Upside: -